Trial Profile

A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 24 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Pazopanib; Sunitinib
Indications Renal cell carcinoma
Focus Registrational; Therapeutic Use
Acronyms KEYNOTE-679/ECHO-302
Sponsors Incyte Corporation

19 Mar 2025 Planned End Date changed from 21 Feb 2025 to 30 Jun 2025.
05 Feb 2025 Planned End Date changed from 31 Dec 2024 to 21 Feb 2025.
25 Jul 2024 Results assessing comparison of pembrolizumab plus epacadostat with sunitinib or pazopanib as first-line treatment for mRCC presented in the BMC Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com